Merck beats Q3 estimates, raises 2026 profit outlook on Keytruda strength

Merck $MRK reported third-quarter earnings of $2.49 per share against consensus estimates of $2.12, a 17.5% beat, with revenue of $18.09 billion outpacing forecasts. The company raised its full-year profit outlook, driven by strong performance of its cancer drug Keytruda in new formulations.

The pharmaceutical giant's results underscore the durability of oncology franchises and successful pipeline execution. Merck's guidance lift reflects confidence in demand trajectories through year-end.

#pharma #earnings #healthcare